Ongoing Interventional Clinical Trial Study Drugs

The Department of Health and Human Services National Institutes of Health Office of Logistics and Acquisition Operations is seeking a contractor to support an ongoing interventional clinical trial involving study drugs. This procurement falls under the Surgical and Medical Instrument Manufacturing NAICS category and specifically targets pharmaceutical procurement for clinical research purposes. The pre-solicitation notice indicates a short response window, with proposals due by May 20, 2025, which suggests a time-sensitive acquisition process. While specific evaluation criteria were not fully detailed in the provided documentation, the opportunity appears to require specialized expertise in clinical trial drug management and pharmaceutical research support. The contract will likely prioritize vendors with demonstrated capabilities in managing complex medical research drug procurement and logistics.

This federal contract opportunity does not have a specific set-aside designation, which means it is open to a broad range of qualified contractors. The procurement is categorized under Product Service Code 6505 for Drugs and Biologicals, indicating a specialized medical supply requirement. Although precise award values were not specified in the pre-solicitation notice, the involvement of the National Institutes of Health suggests potential for a substantial contract with significant research implications. The short timeline between the posting date (May 15, 2025) and the response deadline suggests the agency is seeking to move quickly in selecting a contractor for this interventional clinical trial drug procurement. Potential bidders should be prepared to demonstrate comprehensive understanding of clinical research drug management and robust logistical capabilities.